Pembrolizumab‐induced mucositis in a patient with recurrent hypopharynx squamous cell cancer | Zendy

Pelster Meredith S. | Zendy; Mott Frank | Zendy; Lewin Jan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Pembrolizumab‐induced mucositis in a patient with recurrent hypopharynx squamous cell cancer

Author(s) -

Pelster Meredith S.,

Mott Frank,

Lewin Jan

Publication year - 2020

Publication title -

the laryngoscope

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.181

H-Index - 148

eISSN - 1531-4995

pISSN - 0023-852X

DOI - 10.1002/lary.28038

Subject(s) - medicine , pembrolizumab , mucositis , head and neck cancer , oncology , squamous cell cancer , regimen , head and neck , cancer , chemotherapy , immunotherapy , surgery , dermatology

Pembrolizumab, an anti‐PD‐1 checkpoint inhibitor, is used in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have received prior therapy with a platinum‐based regimen. As a monotherapy, it is generally well tolerated, but a small percentage of patients may develop immune‐mediated inflammatory reactions. We report a case of mucositis and laryngeal edema in a patient on pembrolizumab and review the literature. Laryngoscope , 130:E140–E143, 2020

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research